At the last check on Thursday, Karyopharm Therapeutics Inc.’s (NASDAQ:KPTI) stock was down -$0.04, moving down -2.92 percent to $1.33. The average number of shares traded per day over the past five days has been 950,411 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0550 fall in that time frame. In the last twenty days, the average volume was 1,290,988, while in the previous 50 days, it was 2,607,935.
Since last month, KPTI stock retreated -25.70%. Shares of the company fell to $1.3100 on 08/31/23, the lowest level in the past month. A 52-week high of $6.01 was reached on 04/17/23 after having rallying from a 52-week low of $1.33. Since the beginning of this year, KPTI’s stock price has dropped by -60.88% or -$2.0650, and marked a new high 13 times. However, the stock has declined by -77.87% since its 52-week high.
KPTI stock investors should be aware that Karyopharm Therapeutics Inc. (KPTI) stock had its last reported insider trading activity 24 days ago on Aug 07. Paulson Richard A., the President and CEO of the company, disposed of 3,722 shares for $1.72 on Aug 07. It resulted in a $6,402 divestment by the insider. Poulton Stuart sold 2,845 shares at an average price of $1.70 on Jul 28. The insider now owns 156,286 shares following the transaction. On Jul 05, President and CEO Paulson Richard A. sold 3,538 shares at $1.72 apiece. The transaction was valued at $6,085.
Financial Health
In the three months ended June 29, Karyopharm Therapeutics Inc.’s quick ratio stood at 4.90, while its current ratio was 4.90, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 96.30% percent. In the year ended June 29, EBITDA margin amounted to -90.14%, whereas operating margins totaled -85.70%. Based on annual data, KPTI earned $151.86 million in gross profit and brought in $157.07 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -49.80%. Return on equity (ROE) for the past 12 months was 207.20%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. KPTI’s revenue fell -5.59% to $38.7 million during the quarter, while net income inched up to $37.58 million. While analysts expected Karyopharm Therapeutics Inc. to report -$0.34 quarterly earnings, the actual figure was -$0.29 per share, beating the consensus estimate by 14.70%. During the quarter, the company generated -$30.31 million in EBITDA. The liabilities of Karyopharm Therapeutics Inc. were 369.08 million at the end of its most recent quarter ended June 29, and its total debt was $310.8 million. The value of shareholders’ equity is $114.36 million.
Technical Picture
This quick technical analysis looks at Karyopharm Therapeutics Inc.’s (KPTI) price momentum. With a historical volatility rate of 45.61%, the RSI 9-day stood at 25.08% on 30 August.
With respect to its five-day moving average, the current Karyopharm Therapeutics Inc. price is down by -3.96% percent or -$0.0550. At present, KPTI shares trade -26.24% below its 20-day simple moving average and -65.68% percent below its 100-day simple moving average. However, the stock is currently trading approximately -33.91% below its SMA50 and -76.41% below its SMA200.
Stochastic coefficient K was 4.68% and Stochastic coefficient D was 5.81%, while ATR was 0.1139. Given the Stochastic reading of 4.55% for the 14-day period, the RSI (14) reading has been calculated as 29.85%. As of today, the MACD Oscillator reading stands at -0.0656, while the 14-day reading stands at -0.1661.
Analyst Ratings
Piper Sandler launched its rating on Karyopharm Therapeutics Inc. (NASDAQ: KPTI) to an Overweight in a note to investors on January 19, 2023. Karyopharm Therapeutics Inc. (KPTI) has been rated Overweight by analysts. According to 0 brokerage firms, KPTI is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Karyopharm Therapeutics Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $6.00, the current consensus forecast for the stock is $4.00 – $10.00. Based on these forecasts, analysts predict Karyopharm Therapeutics Inc. (KPTI) will achieve an average price target of $6.50.
